NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, announced that its Phase II clinical trial of NV-387 Oral Gummies for the treatment of Bundibugyo Ebolavirus and other Ebola viruses will begin next week at an Ebola Treatment Center in the Ituri province of the Democratic Republic of Congo (DRC). The trial is an adaptive Phase IIA/IIB design that will first evaluate safety and dosing before moving to a randomized, controlled, open-label efficacy evaluation. Prof. Patrick de Marie Chimusa Katoto is the principal investigator, with Om Sai Clinical Research leading the study. The company expects to dose the first Ebola patient next week, assuming no outbreak-related delays.
NV-387 is an orally administered broad-spectrum antiviral designed to mimic host-side features that Ebola viruses require for infection. NanoViricides believes this mechanism could make viral escape less likely compared to antibody-based treatments. The oral formulation may also offer practical advantages over infusion-based therapies currently under study, especially in resource-constrained areas where intravenous administration can be challenging. The company cautioned that clinical trial data will ultimately determine whether NV-387 is effective against Ebola. The trial is launching amid a rapidly expanding Bundibugyo Ebolavirus outbreak in the DRC.
For readers and industry observers, this development matters because it represents a potential shift in how Ebola is treated. If successful, an oral antiviral could simplify treatment logistics, reduce the need for specialized infusion equipment, and enable faster deployment during outbreaks. The broader implications for global health are significant: Ebola outbreaks often occur in regions with limited healthcare infrastructure, and an easy-to-administer pill could improve patient access and outcomes. The trial also highlights the growing interest in broad-spectrum antivirals that could target multiple viruses, a trend that may reshape preparedness for emerging infectious diseases.
NanoViricides is a clinical-stage company creating special purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is being developed for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and Measles. The company’s other advanced candidate is NV-HHV-1 for Shingles. NanoViricides’ platform technology is based on the TheraCour® nanomedicine technology, licensed from TheraCour Pharma, Inc. The company holds a worldwide exclusive perpetual license for several drugs targeting major human viral diseases, including HIV/AIDS, Hepatitis B and C, Rabies, Herpes Simplex, Varicella-Zoster, Influenza, Dengue, Japanese Encephalitis, West Nile, Ebola/Marburg, and certain Coronaviruses.
For more details, the full press release is available at https://ibn.fm/21nLx. The latest news and updates relating to NNVC can be found in the company’s newsroom at https://ibn.fm/NNVC. Additional information about InvestorWire is at https://www.InvestorWire.com, and terms of use and disclaimers are at https://www.InvestorWire.com/Disclaimer.
